DUBLIN--(BUSINESS WIRE)--The "Gorlin Syndrome - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Gorlin Syndrome Pipeline Insight, 2020 outlays comprehensive ...

SAN FRANCISCO--(BUSINESS WIRE)--PellePharm, Inc., a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, today announced it has dosed the ...

Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) ...

Gorlin Syndrome is a rare, genetic disease characterized by mutations in the tumor suppressor gene encoding Patched1 The Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation ...

Doctors and scientists have identified changes in a gene, which can increase the risk of developing brain tumors in children with a rare inherited condition called Gorlin syndrome. Most people with ...

Patched-1, or PTCH1, is a tumor suppressor gene, meaning it helps prevent certain types of cancers from developing. When you have a PTCH1 mutation, the gene’s cancer-suppressing effect no longer works ...

Meier-Gorlin syndrome, or MGS, is a rare genetic developmental disorder that causes dwarfism, small ears, a small brain, missing patella and other skeletal abnormalities. In severe cases, MGS results ...

PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs ...

The Gorlin Syndrome Alliance is a U.S.-based 501 (c) (3) nonprofit organization with a stated mission to “thoughtfully support, comprehensively educate, and aggressively seek the best treatments and a ...